Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Alere and VitaPath Genetics to create birth defect diagnostics

Alere and VitaPath Genetics to create birth defect diagnostics

15th August 2011

Alere is entering into a new alliance with VitaPath Genetics on the development of molecular diagnostic tools for use in the prevention of birth defects.

The agreement will see Alere gain worldwide marketing rights to a spina bifida risk assessment assay from VitaPath, which is expected to make its commercial debut in 2012.

In addition, a deal has been agreed that will see the two companies working together to create additional product line extensions in the field of foetal health, with financial terms of the transaction remaining undisclosed.

The new assay will be used to identify elevated risk among women of childbearing age for the common birth defect spina bifida, which will help these patients to receive appropriate treatment.

Ron Zwanziger, chairman, chief executive officer and president of Alere, said: "We look forward to working with VitaPath to launch this new test and to develop new, exciting risk assessment tools for healthy pregnancies."

Earlier this month, the company announced that it will be acquiring an expanded stake in Axis-Shield, a fellow life sciences-focused company.ADNFCR-8000103-ID-800700353-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.